- Home
- AR vs BMRN Comparison
AR vs BMRN Comparison
Compare AR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AR | BMRN |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.0B |
| IPO Year | 2013 | 1999 |
Fundamental Metrics
Financial Performance| Metric | AR | BMRN |
|---|---|---|
| Price | $38.75 | $60.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 16 |
| Target Price | $44.63 | ★ $87.38 |
| AVG Volume (30 Days) | ★ 5.3M | 2.3M |
| Earning Date | 05-14-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1027.78 | N/A |
| EPS | ★ 2.03 | 1.80 |
| Revenue | ★ $5,275,823,000.00 | $1,313,646,000.00 |
| Revenue This Year | $23.61 | $13.34 |
| Revenue Next Year | $6.22 | $11.42 |
| P/E Ratio | ★ $19.08 | $34.15 |
| Revenue Growth | ★ 21.97 | 17.62 |
| 52 Week Low | $29.10 | $50.76 |
| 52 Week High | $44.02 | $73.18 |
Technical Indicators
Market Signals| Indicator | AR | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 67.53 | 53.15 |
| Support Level | $32.27 | $56.08 |
| Resistance Level | $40.42 | $64.71 |
| Average True Range (ATR) | 1.30 | 2.45 |
| MACD | 0.43 | -0.22 |
| Stochastic Oscillator | 82.10 | 29.58 |
Price Performance
Historical ComparisonAbout AR Antero Resources Corporation
Antero Resources, based in Denver, explores for and produces natural gas and natural gas liquids in the United States and Canada. At the end of 2025, the company reported proven reserves of 19.1 trillion cubic feet of natural gas equivalent. Production averaged approximately 3,442 million cubic feet of equivalent per day in 2025 at a ratio of 35% liquids and 65% natural gas.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.